CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 10,917 enrolled
Drug / intervention
Ivabradine +1 moredrug
Likely dose
Not stated in record
Key inclusion· 3
  • ✓Coronary artery disease
  • ✓Left ventricular systolic dysfunction
  • ✓Sinus rhythm with heart rate ≥60 beats per minute
Key exclusion· 2
  • ✕Unstable cardiovascular condition
  • ✕Severe congestive heart failure

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00143507
NCT00143507Phase 3Completed
CompareCT.gov

Effects of Ivabradine on Cardiovascular Events in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction. A Three-year Randomised Double-blind Placebo-controlled International Multicentre Study.

Institut de Recherches Internationales Servier·interventional·Posted Sep 2, 2005·Updated Apr 12, 2018

In Brief

A Phase 3 clinical trial evaluating Ivabradine and Placebo for Coronary Disease and Ventricular Dysfunction, Left. Completed, enrolled 10,917 participants across 1 site.

Detailed Summary

The aim of this study is to test whether ivabradine is able to reduce cardiovascular events when given to patients with coronary artery disease and impaired heart function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease, Ventricular Dysfunction, Left
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2, 2005
Enrollment StartDec 1, 2004
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 20.8 years ago

Interventions

Ivabradinedrug

Placebodrug